

Eva Colas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4520990/publications.pdf>

Version: 2024-02-01

57
papers

6,001
citations

172207

29
h-index

143772

57
g-index

59
all docs

59
docs citations

59
times ranked

11548
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. <i>Oncogene</i> , 2022, 41, 1835-1850.	2.6	9
2	Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6266.	1.8	6
3	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2021, 109, 80-91.	1.1	22
4	Modeling ANXA2-overexpressing circulating tumor cells homing and high throughput screening for metastasis impairment in endometrial carcinomas. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111744.	2.5	2
5	In silico Approach for Validating and Unveiling New Applications for Prognostic Biomarkers of Endometrial Cancer. <i>Cancers</i> , 2021, 13, 5052.	1.7	8
6	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. <i>PLoS Medicine</i> , 2020, 17, e1003111.	3.9	25
7	Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1900.	1.0	67
8	Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 585.	1.0	23
9	Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer. <i>Cancers</i> , 2020, 12, 2751.	1.7	12
10	Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools. <i>Oncology Reports</i> , 2020, 44, 873-886.	1.2	10
11	Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 492-500.	0.3	42
12	Clinical management of early-stage cervical cancer: The role of sentinel lymph node biopsy in tumors ≤ 2 cm. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 241, 30-34.	0.5	5
13	EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer. <i>Scientific Reports</i> , 2019, 9, 15057.	1.6	31
14	EV-Associated miRNAs from Peritoneal Lavage are a Source of Biomarkers in Endometrial Cancer. <i>Cancers</i> , 2019, 11, 839.	1.7	27
15	EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 208.	1.8	30
16	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. <i>British Journal of Cancer</i> , 2019, 120, 1037-1044.	2.9	10
17	Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 153, 425-435.	0.6	30
18	Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. <i>Cancers</i> , 2019, 11, 2000.	1.7	30

#	ARTICLE	IF	CITATIONS
19	FXVD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF- β 1 and NF- κ B Pathways. <i>Frontiers in Oncology</i> , 2019, 9, 1306.	1.3	15
20	Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 514-523.	1.2	43
21	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. <i>International Journal of Cancer</i> , 2018, 142, 1230-1243.	2.3	59
22	Advances in endometrial cancer protein biomarkers for use in the clinic. <i>Expert Review of Proteomics</i> , 2018, 15, 81-99.	1.3	20
23	Patient-Derived Xenograft Models for Endometrial Cancer Research. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2431.	1.8	32
24	ALCAM shedding at the invasive front of the tumor is a marker of myometrial infiltration and promotes invasion in endometrioid endometrial cancer. <i>Oncotarget</i> , 2018, 9, 16648-16664.	0.8	11
25	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomasâ€”an ENITEC Group Initiative. <i>Clinical Cancer Research</i> , 2017, 23, 1274-1285.	3.2	30
26	Endometrial Carcinoma: Specific Targeted Pathways. <i>Advances in Experimental Medicine and Biology</i> , 2017, 943, 149-207.	0.8	53
27	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 1551-1563.	2.3	30
28	Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis. <i>Scientific Reports</i> , 2017, 7, 8803.	1.6	30
29	Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 6458-6467.	3.2	50
30	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. <i>Modern Pathology</i> , 2017, 30, 134-145.	2.9	36
31	Activated leukocyte cell adhesion molecule (<scp>ALCAM</scp>) is a marker of recurrence and promotes cell migration, invasion, and metastasis in earlyâ€”stage endometrioid endometrial cancer. <i>Journal of Pathology</i> , 2017, 241, 475-487.	2.1	42
32	L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. <i>British Journal of Cancer</i> , 2016, 115, 716-724.	2.9	76
33	Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols. <i>Journal of Translational Medicine</i> , 2016, 14, 180.	1.8	64
34	Enabling Metabolomics Based Biomarker Discovery Studies Using Molecular Phenotyping of Exosome-Like Vesicles. <i>PLoS ONE</i> , 2016, 11, e0151339.	1.1	70
35	Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism. <i>Oncotarget</i> , 2016, 7, 52364-52374.	0.8	17
36	Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. <i>Oncotarget</i> , 2016, 7, 53102-53115.	0.8	24

#	ARTICLE	IF	CITATIONS
37	Annexin A2 as predictor biomarker of recurrent disease in endometrial cancer. <i>International Journal of Cancer</i> , 2015, 136, 1863-1873.	2.3	39
38	Biological properties of extracellular vesicles and their physiological functions. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 27066.	5.5	3,973
39	Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 467-478.	1.7	40
40	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. <i>Molecular Cancer</i> , 2014, 13, 223.	7.9	88
41	MicroRNAs as prognostic markers in ovarian cancer. <i>Molecular and Cellular Endocrinology</i> , 2014, 390, 73-84.	1.6	30
42	Coexistence of homologous-type cervical carcinosarcoma with endometrioid-type G1 endometrial cancer: a case report with an immunohistochemical study. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 7191-5.	0.5	6
43	Molecular diagnosis of endometrial cancer from uterine aspirates. <i>International Journal of Cancer</i> , 2013, 133, 2383-2391.	2.3	15
44	Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues. <i>BioMed Research International</i> , 2013, 2013, 1-15.	0.9	12
45	The Present and Future of Prostate Cancer Urine Biomarkers. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12620-12649.	1.8	56
46	The EMT signaling pathways in endometrial carcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 715-720.	1.2	95
47	Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. <i>Molecular and Cellular Endocrinology</i> , 2012, 358, 244-255.	1.6	54
48	ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. <i>International Journal of Cancer</i> , 2012, 130, 1532-1543.	2.3	50
49	Generation and characterization of orthotopic murine models for endometrial cancer. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 217-227.	1.7	26
50	A Three Gene panel on urine increases PSA specificity in the detection of prostate cancer. <i>Prostate</i> , 2011, 71, 1736-1745.	1.2	43
51	Molecular markers of endometrial carcinoma detected in uterine aspirates. <i>International Journal of Cancer</i> , 2011, 129, 2435-2444.	2.3	105
52	High-Risk Endometrial Carcinoma Profiling Identifies TGF- β 1 as a Key Factor in the Initiation of Tumor Invasion. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1357-1366.	1.9	41
53	PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. <i>Prostate</i> , 2010, 70, 1760-1767.	1.2	63
54	Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. <i>Carcinogenesis</i> , 2009, 30, 1288-1297.	1.3	50

#	ARTICLE	IF	CITATIONS
55	An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. International Journal of Cancer, 2009, 125, 257-263.	2.3	44
56	Subtractive Proteomic Approach to the Endometrial Carcinoma Invasion Front. Journal of Proteome Research, 2009, 8, 4676-4684.	1.8	22
57	ERM/ETV5 Up-regulation Plays a Role during Myometrial Infiltration through Matrix Metalloproteinase-2 Activation in Endometrial Cancer. Cancer Research, 2007, 67, 6753-6759.	0.4	57